Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$73.71 USD

73.71
3,674,571

+0.41 (0.56%)

Updated Jul 18, 2024 02:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues

by Zacks Equity Research

FATE reports a wider loss on increased R&D expenses in the second quarter.

Intercept's (ICPT) Q2 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research

Intercept (ICPT) posts a narrower loss in the second quarter and sales beat estimates.

Gilead (GILD) Q2 Earnings Beat Estimates, HIV Sales Decline

by Zacks Equity Research

Gilead (GILD) beats on sales and earnings in the second quarter. While the HIV business lags due to generic competition, Veklury maintains momentum.

Ligand (LGND) Q2 Earnings & Sales Beat, 2021 Guidance Cut

by Zacks Equity Research

Ligand (LGND) reports encouraging second-quarter 2021 numbers by beating estimates on both counts.

Mark Vickery headshot

Q2 Earnings Beats Don't Stop Late-Market Selloffs

by Mark Vickery

Amazon (AMZN) beat earnings estimates for its Q2, but the stock is falling -6.3% in late trading.

Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of 6.25% and 1.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Gilead (GILD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports second-quarter 2021 results.

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Killa headshot

Healthcare ETFs in Focus as Q2 Earnings Unfold

by Sweta Killa

The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $68.41 in the latest trading session, marking a -1.08% move from the prior day.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $68.30, marking a +0.54% move from the previous day.

Galapagos (GLPG) Falls on Inflammatory Study Data Readout

by Zacks Equity Research

Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.

The Zacks Analyst Blog Highlights: JPMorgan, Intel, McDonald's, CME Group and Gilead Sciences

by Zacks Equity Research

The Zacks Analyst Blog Highlights: JPMorgan, Intel, McDonald's, CME Group and Gilead Sciences

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $68.22, moving +0.78% from the previous trading session.

Sheraz Mian headshot

Top Stock Reports for JPMorgan, Intel & McDonald's

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Intel (INTC), and McDonald's (MCD).

Gilead (GILD) Gains 19% YTD: What to Expect in The Second Half?

by Zacks Equity Research

Gilead (GILD) maintains momentum in the year so far on the back of Veklury for the treatment of COVID-19 and the same is expected to continue in the second half.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $68.86, moving +1.37% from the previous trading session.

Gilead's (GILD) Kite Announces Positive Data on Yescarta

by Zacks Equity Research

Gilead (GILD) announces results from the ZUMA-7 study on Yescarta and completes submission of application to the FDA seeking approval of lenacapavir.

Roche's (RHHBY) Actemra Gets FDA Emergency Nod for COVID-19

by Zacks Equity Research

The FDA issues an Emergency Use Authorization for Roche's (RHHBY) Actemra for the treatment of COVID-19 in hospitalized adults and pediatric patients.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $67.18 in the latest trading session, marking a +0.8% move from the prior day.

Gilead (GILD) Veklury Data Positive in Hospitalized COVID Patients

by Zacks Equity Research

Gilead (GILD) announces positive data on Veklury in hospitalized patients with COVID-19 across three analyses of large retrospective real-world data sets.

Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies

by Zacks Equity Research

Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $67.22, marking a -0.16% move from the previous day.

Neena Mishra headshot

Should You Buy Biotech ETFs Now?

by Neena Mishra

Biotech stocks are rallying this month; can the trend continue?

Cocrystal's (COCP) Antiviral CDI-45205 Effective Against COVID-19

by Zacks Equity Research

Cocrystal (COCP) SARS-CoV-2 3CL protease inhibitor, CDI-45205, found to be effective in treating the original and two other variants of the COVID-19 virus. Shares up.